~80%-90% of patients
with prostate cancer
remain castration sensitive within 5 years of follow-up
from diagnosis3*
~10%-20% of patients with prostate cancer progress to castration-resistant disease within 5 years of follow-up3*
~39% of mCRPC patients in the US are positive for HRR mutations4†
~20% of mCRPC patients in the US are positive for BRCA mutations specifically4†
*Percentages are from an observation based on a systematic review of 5 studies that included 70,086 patients observed for up to 12 years.
†Based on a global survey conducted in 2020 of mCRPC patients with BRCA or other HRR mutations. Percentages and ns shown are from the US population.
BRCA, BReast CAncer gene; HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; PARPi, poly (adenosine diphosphate-ribose) polymerase inhibitor.
RUBRACA® (rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
In ARIEL3, of patients with a germline and/or somatic BRCA mutation treated with RUBRACA, MDS/AML occurred in 9 out of 129 (7%) patients treated with RUBRACA and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.2 to 4.7 years.
Most common adverse reactions of patients with BRCA-mutated mCRPC in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), anemia (43%), AST/ALT elevation (33%), decreased appetite (28%), rash (27%), constipation (27%), thrombocytopenia (25%), vomiting (22%), and diarrhea (20%).
